Cardiac allograft vasculopathy: A review

Area of Science:

• Pediatric Cardiology
• Transplantation Immunology
• Cardiovascular Research

Background:

• Pediatric heart transplantation outcomes have improved, but cardiac allograft vasculopathy (CAV) remains a primary cause of death beyond three years.
• CAV significantly impacts morbidity and mortality in pediatric heart transplant recipients.
• Understanding CAV is critical for improving long-term graft survival in children.

Purpose of the Study:

• To provide a comprehensive overview of CAV in pediatric heart transplant recipients.
• To discuss the clinical presentation, risk factors, and diagnostic challenges of CAV.
• To highlight current therapeutic strategies and research needs for pediatric CAV.

Main Methods:

• Systematic literature search of Medline and Embase databases.
• Inclusion of articles in English focusing on pediatric heart transplant recipients and CAV.
• Analysis of identified articles for etiology, diagnosis, prognosis, risk factors, and treatment.

Main Results:

• Limited pediatric data exists on CAV etiology and development, though immune and non-immune factors are increasingly recognized.
• Current diagnostic methods for CAV are suboptimal, with no proven interventions to reverse established disease.
• CAV is linked to high graft loss rates, necessitating preventative and disease-modifying therapies.

Conclusions:

• This review synthesizes current knowledge on pediatric CAV, including its presentation, risk factors, and diagnostics.
• Effective management of CAV in pediatric heart transplant patients requires further research into novel therapeutic options.
• Addressing CAV is essential for improving long-term outcomes and reducing graft loss in this vulnerable population.